- Home
- GCMG vs ATXS Comparison
GCMG vs ATXS Comparison
Compare GCMG & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCMG | ATXS |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.5M | 722.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GCMG | ATXS |
|---|---|---|
| Price | $11.64 | $12.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | $15.67 | ★ $24.33 |
| AVG Volume (30 Days) | 961.8K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $543,085,000.00 | $706,000.00 |
| Revenue This Year | $6.58 | N/A |
| Revenue Next Year | $9.84 | N/A |
| P/E Ratio | $36.46 | ★ N/A |
| Revenue Growth | ★ 17.40 | N/A |
| 52 Week Low | $10.23 | $3.56 |
| 52 Week High | $14.48 | $13.29 |
Technical Indicators
Market Signals| Indicator | GCMG | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 65.69 |
| Support Level | $10.47 | $12.70 |
| Resistance Level | $11.39 | $13.29 |
| Average True Range (ATR) | 0.31 | 0.22 |
| MACD | 0.13 | -0.05 |
| Stochastic Oscillator | 92.11 | 67.84 |
Price Performance
Historical ComparisonAbout GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.